The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T.
Shimose S, et al. Among authors: koga h.
Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6.
Hepatol Res. 2023.
PMID: 36149726